Policy | July 27, 2022
Bulk Drug Park in the country :PIB
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey
The tenure of contract will be upto 10 years from date of signing the contract/installation.
The product will be manufactured at Lupin's facility in Nagpur, India.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
Subscribe To Our Newsletter & Stay Updated
